Bulletin
Investor Alert

New York Markets Close in:

Allakos Inc.

NAS: ALLK

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 31, 2023, 2:40 p.m.

/zigman2/quotes/203639566/composite

$

7.43

Change

+0.21 +2.84%

Volume

Volume 371,880

Real time quotes

/zigman2/quotes/203639566/composite

Previous close

$ 7.22

$ 7.43

Change

+0.21 +2.84%

Day low

Day high

$7.24

$7.46

Open

52 week low

52 week high

$2.54

$8.73

Open

Company Description

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocy...

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Valuation

Price to Book Ratio

1.20

Enterprise Value to EBITDA

-0.91

Efficiency

Liquidity

Current Ratio

11.22

Quick Ratio

11.22

Cash Ratio

10.54

Profitability

Return on Assets

-43.02

Return on Equity

-49.07

Return on Total Capital

-45.45

Capital Structure

Total Debt to Total Assets

9.61

Officers and Executives

Name Age Officer Since Title
Dr. Robert Alexander 51 2017 Chief Executive Officer & Director
Dr. Adam L. Tomasi 51 2017 President & Chief Operating Officer
Mr. Harlan Baird Radford - 2021 Chief Financial Officer
Dr. Ruby Casareno - - Vice President-Technical Operations
Dr. Craig Paterson - 2021 SVP-Clinical Development & Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/06/2023 Robert Alexander
Chief Executive Officer; Director
301,575   Award at $0 per share. 0
01/06/2023 Adam L. Tomasi
President
195,997   Award at $0 per share. 0
01/06/2023 Harlan Baird Radford
Chief Financial Officer
126,640   Award at $0 per share. 0
01/06/2023 Craig Paterson
Chief Medical Officer
102,690   Award at $0 per share. 0
12/02/2022 Robert Alexander
Chief Executive Officer; Director
15,152   Derivative/Non-derivative trans. at $8.11 per share. 122,882
12/02/2022 Adam L. Tomasi
President
9,783   Derivative/Non-derivative trans. at $8.11 per share. 79,340
12/02/2022 Harlan Baird Radford
Chief Financial Officer
3,843   Derivative/Non-derivative trans. at $8.11 per share. 31,166
12/02/2022 Craig Paterson
Chief Medical Officer
4,863   Derivative/Non-derivative trans. at $8.11 per share. 39,438
09/21/2022 Alta Partners Management Corp.
Director
475,000   Acquisition at $5.02 per share. 2,384,500
09/21/2022 NEA Management Co. LLC
Director
3,386,400   Acquisition at $5.02 per share. 16,999,728
09/21/2022 NEA Management Co. LLC
Director
597,600   Acquisition at $5.02 per share. 2,999,952
09/02/2022 Robert Alexander
Chief Executive Officer; Director
8,316   Derivative/Non-derivative trans. at $4.54 per share. 37,754
09/02/2022 Adam L. Tomasi
President
5,369   Derivative/Non-derivative trans. at $4.54 per share. 24,375
09/02/2022 Harlan Baird Radford
Chief Financial Officer
585   Derivative/Non-derivative trans. at $4.54 per share. 2,655
09/02/2022 Craig Paterson
Chief Medical Officer
1,129   Derivative/Non-derivative trans. at $4.54 per share. 5,125
09/02/2022 Margaret Fitzgerald
General Counsel and Secretary
335   Derivative/Non-derivative trans. at $4.54 per share. 1,520
06/02/2022 Robert Alexander
Chief Executive Officer; Director
8,084   Derivative/Non-derivative trans. at $2.75 per share. 22,231
06/02/2022 Adam L. Tomasi
President
5,219   Derivative/Non-derivative trans. at $2.75 per share. 14,352
06/02/2022 Harlan Baird Radford
Chief Financial Officer
2,274   Derivative/Non-derivative trans. at $2.75 per share. 6,253
06/02/2022 Craig Paterson
Chief Medical Officer
226   Derivative/Non-derivative trans. at $2.75 per share. 621
06/02/2022 Margaret Fitzgerald
General Counsel and Secretary
318   Derivative/Non-derivative trans. at $2.75 per share. 874
04/19/2022 Margaret Fitzgerald
General Counsel and Secretary
57,637   Award at $0 per share. 0
03/02/2022 Robert Alexander
Chief Executive Officer; Director
8,215   Derivative/Non-derivative trans. at $5.38 per share. 44,196
03/02/2022 Adam L. Tomasi
President
5,582   Derivative/Non-derivative trans. at $5.38 per share. 30,031
03/02/2022 Mark A. Asbury
CLO
1,680   Derivative/Non-derivative trans. at $5.38 per share. 9,038
02/25/2022 Robert Alexander
Chief Executive Officer; Director
529,323   Award at $0 per share. 0
02/25/2022 Adam L. Tomasi
President
344,060   Award at $0 per share. 0
02/25/2022 Harlan Baird Radford
Chief Financial Officer
237,608   Award at $0 per share. 0
02/25/2022 Mark A. Asbury
CLO
140,490   Award at $0 per share. 0
12/02/2021 Robert Alexander
Chief Executive Officer; Director
20,241   Derivative/Non-derivative trans. at $78.69 per share. 1,592,764
12/02/2021 Adam L. Tomasi
President
13,067   Derivative/Non-derivative trans. at $78.69 per share. 1,028,242
12/01/2021 Robert Alexander
Chief Executive Officer; Director
51,681   Award at $0 per share. 0
12/01/2021 Adam L. Tomasi
President
33,362   Award at $0 per share. 0
12/01/2021 Harlan Baird Radford
Chief Financial Officer
24,255   Award at $0 per share. 0
12/01/2021 Mark A. Asbury
CLO
26,003   Award at $0 per share. 0
/news/latest/company/us/allk

MarketWatch News on ALLK

  1. Alkermes, Allakos See Activist Action

    8:30 p.m. Oct. 14, 2022

    - Barron's Online

  2. 8 Biotechs So Cheap Their Technology Is Effectively Free

    5:34 p.m. Feb. 16, 2022

    - Barron's Online

  3. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    7:32 a.m. May 21, 2021

    - Barron's Online

  4. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  5. Allakos started at buy at BofA Securities

    10:31 a.m. Jan. 15, 2021

    - Tomi Kilgore

  6. Allakos stock jumps in afternoon trading

    3:24 p.m. Dec. 4, 2019

    - Jaimy Lee

  7. Allakos's stock rally adds over $2 billion to biotech's market cap

    2:54 p.m. Dec. 4, 2019

    - Tomi Kilgore

  8. Allakos's stock runs up 43% to record high

    2:53 p.m. Dec. 4, 2019

    - Tomi Kilgore

  9. Charting a bullish reversal, S&P 500 extends rally from major support

    10:53 a.m. Aug. 19, 2019

    - Michael Ashbaugh

  10. How 2018’s Major IPOs Performed

    8:39 p.m. Dec. 21, 2018

    - Barron's Online

  11. Glenn Krevlin Wants a Seat at Destination XL

    12:22 a.m. Sept. 15, 2018

    - Barron's Online

  12. ADP and Pershing Square Face Off

    9:35 p.m. Aug. 3, 2018

    - Barron's Online

  13. Biotech Allakos shares surge more than 70% in trading debut

    12:50 p.m. July 19, 2018

    - Ciara Linnane

  14. Allakos shares surge 73% in trading debut

    12:48 p.m. July 19, 2018

    - Ciara Linnane

  15. Biotech Allakos prices IPO at $18, above price range

    6:50 a.m. July 19, 2018

    - Ciara Linnane

  16. Allakos prices IPO at $18 a share

    6:41 a.m. July 19, 2018

    - Ciara Linnane

/news/nonmarketwatch/company/us/allk

Other News on ALLK

  1. 10-Q: ALLAKOS INC.

    4:16 p.m. Nov. 7, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. AVCT, MSC and VTAQ among mid-day movers

    12:06 p.m. Sept. 19, 2022

    - Seeking Alpha

  3. Allakos prices ~$150M underwritten offering

    6:21 a.m. Sept. 19, 2022

    - Seeking Alpha

  4. Why Allakos Stock Is on Fire Today

    1:10 p.m. Aug. 31, 2022

    - Motley Fool

  5. AREC, TMC, AZRE among mid-day movers

    11:45 a.m. Aug. 31, 2022

    - Seeking Alpha

  6. CRMD, CALA and TBLT among mid-day movers

    11:50 a.m. July 20, 2022

    - Seeking Alpha

  7. BLUE, NEPT and MNTS among mid-day movers

    11:30 a.m. June 17, 2022

    - Seeking Alpha

  8. Allakos announces $250M shelf offering

    4:36 p.m. May 6, 2022

    - Seeking Alpha

  9. 10-Q: ALLAKOS INC.

    3:09 p.m. May 6, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  10. Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

    3:23 p.m. March 8, 2022

    - Seeking Alpha

  11. Loading more headlines...

At a Glance

Allakos, Inc.

825 Industrial Road

Suite 500

San Carlos, California 94070

Phone

1 6505975002

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-269.86M

Employees

192.00

/news/pressrelease/company/us/allk

Press Releases on ALLK

  1. Monday 9/26 Insider Buying Report: ALLK, CRK

    9:31 a.m. Sept. 26, 2022

    - MarketNewsVideo.com

  2. Allakos to Host Investor Day on February 15

    8:00 a.m. Feb. 1, 2022

    - GlobeNewswire

  3. Loading more headlines...
Link to MarketWatch's Slice.